GLP-1 receptor agonists for weight loss
Pro Research Analysisby 
Searched over 200M research papers
GLP-1 Receptor Agonists for Weight Loss: Mechanism and Efficacy
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medications originally developed for type 2 diabetes but have shown significant benefits for weight loss in people with obesity or overweight, both with and without diabetes. These drugs work by reducing appetite through central nervous system effects and slowing gastric emptying, leading to reduced calorie intake and weight loss De Moraes2024Scheen2021Wang2023.
Large-scale studies and meta-analyses consistently show that GLP-1 RAs, including liraglutide, semaglutide, and tirzepatide, lead to significant reductions in body weight, body mass index (BMI), and waist circumference compared to placebo Moiz2025Liu2023Wong2025+1 MORE. The weight loss effect is dose-dependent, with higher doses producing greater weight reduction Liu2023Scheen2021. Among available agents, semaglutide and tirzepatide have demonstrated the most substantial weight loss, with semaglutide leading to up to 13.9% weight loss and tirzepatide up to 17.8% in adults without diabetes over 68–72 weeks of treatment Moiz2025Liu2023. Newer agents like retatrutide may offer even greater effects .
GLP-1 RAs in Special Populations and Administration Routes
GLP-1 RAs are effective across diverse populations, including peri- and postmenopausal women, who often struggle with weight gain during these life stages . While most GLP-1 RAs are injectable, oral formulations such as oral semaglutide are being developed to improve accessibility and patient adherence, although injectable forms remain the most effective to date Krinsky2024Myerson2024.
Safety and Adverse Effects of GLP-1 Receptor Agonists
The most common side effects of GLP-1 RAs are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These adverse events are usually mild to moderate and tend to decrease over time, but they can lead to treatment discontinuation in some cases Moiz2025Liu2023Wong2025+1 MORE. Serious adverse events are rare, and overall, the benefit-risk profile is favorable for most patients, especially when other weight loss interventions have failed De Moraes2024Moiz2025Wong2025.
Long-Term Use, Maintenance, and Considerations
GLP-1 RAs not only help with initial weight loss but also support long-term weight maintenance when used continuously De Moraes2024Wong2025. Their use should be personalized, considering individual patient characteristics, potential side effects, and cost or reimbursement issues De Moraes2024Myerson2024Moore2022. Ongoing research is needed to better understand their long-term safety, especially in specific populations such as peri- and postmenopausal women De Moraes2024Mikdachi2025.
Conclusion
GLP-1 receptor agonists are among the most effective pharmacological options for weight loss in adults with obesity or overweight, with or without diabetes. They offer significant reductions in weight, BMI, and waist circumference, with a safety profile dominated by manageable gastrointestinal side effects. Personalization of therapy and further research into long-term outcomes and special populations will help optimize their use in clinical practice De Moraes2024Moiz2025Liu2023+6 MORE.
Sources and full results
Most relevant research papers on this topic